Literature DB >> 22270280

Nodal metastasis risk in endometrioid endometrial cancer.

Michael R Milam1, James Java, Joan L Walker, Daniel S Metzinger, Lynn P Parker, Robert L Coleman.   

Abstract

OBJECTIVE: To estimate the risk for nodal metastasis in women with endometrial cancer based on uterine characteristics on pathology.
METHODS: From a study of staging for uterine cancer, women were identified as being at low risk for nodal metastasis based on three specific criteria on final pathology reports: 1) less than 50% invasion, 2) tumor size less than 2 cm, and 3) well or moderately differentiated endometrioid histology. If the uterine specimen did not meet all three criteria, it was viewed as high risk for nodal metastasis.
RESULTS: Nine hundred seventy-one women were included in this analysis. Approximately 40% (or 389 of 971) of patients in this study were found to be at low risk, with a rate of nodal metastasis of only 0.8% (3 of 389; exact 95% confidence interval [CI] 0.16-2.2). No statistical differences in median age, body mass index, race, performance status, missing clinical data, or open or minimally invasive techniques were found among the patients with and without nodal metastases. Patients with high-risk characteristics of their uterine specimens compared with those with low-risk characteristics have 6.3 times the risk of nodal metastasis (95% CI 1.67-23.8, P=.007).
CONCLUSION: Low-risk endometrioid uterine cancer criteria may be used to help guide treatment planning for reoperation in patients with incomplete surgical staging information. LEVEL OF EVIDENCE: II.

Entities:  

Mesh:

Year:  2012        PMID: 22270280      PMCID: PMC3266531          DOI: 10.1097/AOG.0b013e318240de51

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  20 in total

1.  Therapeutic role of lymph node resection in endometrioid corpus cancer: a study of 12,333 patients.

Authors:  John K Chan; Michael K Cheung; Warner K Huh; Kathryn Osann; Amreen Husain; Nelson N Teng; Daniel S Kapp
Journal:  Cancer       Date:  2006-10-15       Impact factor: 6.860

2.  ACOG practice bulletin, clinical management guidelines for obstetrician-gynecologists, number 65, August 2005: management of endometrial cancer.

Authors: 
Journal:  Obstet Gynecol       Date:  2005-08       Impact factor: 7.661

3.  Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study.

Authors:  W T Creasman; C P Morrow; B N Bundy; H D Homesley; J E Graham; P B Heller
Journal:  Cancer       Date:  1987-10-15       Impact factor: 6.860

4.  Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study.

Authors:  Cornelia L Trimble; James Kauderer; Richard Zaino; Steven Silverberg; Peter C Lim; James J Burke; David Alberts; John Curtin
Journal:  Cancer       Date:  2006-02-15       Impact factor: 6.860

5.  Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology.

Authors:  Christopher V Lutman; Laura J Havrilesky; Janiel M Cragun; Angeles Alvarez Secord; Brian Calingaert; Andrew Berchuck; Daniel L Clarke-Pearson; John T Soper
Journal:  Gynecol Oncol       Date:  2006-01-10       Impact factor: 5.482

6.  Tumor size in endometrial cancer: a prognostic factor for lymph node metastasis.

Authors:  J C Schink; J R Lurain; C B Wallemark; J S Chmiel
Journal:  Obstet Gynecol       Date:  1987-08       Impact factor: 7.661

7.  The outcomes of 27,063 women with unstaged endometrioid uterine cancer.

Authors:  John K Chan; Huahsi Wu; Michael K Cheung; Jacob Y Shin; Kathryn Osann; Daniel S Kapp
Journal:  Gynecol Oncol       Date:  2007-08       Impact factor: 5.482

8.  Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging.

Authors:  Andrea Mariani; Sean C Dowdy; William A Cliby; Bobbie S Gostout; Monica B Jones; Timothy O Wilson; Karl C Podratz
Journal:  Gynecol Oncol       Date:  2008-03-04       Impact factor: 5.482

9.  Accuracy of preoperative endometrial sampling diagnosis of FIGO grade 1 endometrial adenocarcinoma.

Authors:  Mario M Leitao; Siobhan Kehoe; Richard R Barakat; Kaled Alektiar; Leda P Gattoc; Catherine Rabbitt; Dennis S Chi; Robert A Soslow; Nadeem R Abu-Rustum
Journal:  Gynecol Oncol       Date:  2008-08-27       Impact factor: 5.482

10.  Lymphadenectomy in endometrioid uterine cancer staging: how many lymph nodes are enough? A study of 11,443 patients.

Authors:  John K Chan; Renata Urban; Michael K Cheung; Jacob Y Shin; Amreen Husain; Nelson N Teng; Jonathan S Berek; Joan L Walker; Daniel S Kapp; Kathryn Osann
Journal:  Cancer       Date:  2007-06-15       Impact factor: 6.860

View more
  33 in total

1.  Endometrial cancer.

Authors:  Kimberly K Leslie; Kristina W Thiel; Michael J Goodheart; Koen De Geest; Yichen Jia; Shujie Yang
Journal:  Obstet Gynecol Clin North Am       Date:  2012-06       Impact factor: 2.844

2.  Three Lymphadenectomy Strategies in Low-Risk Endometrial Carcinoma: A Cost-Effectiveness Analysis.

Authors:  Rudy S Suidan; Charlotte C Sun; Scott B Cantor; Andrea Mariani; Pamela T Soliman; Shannon N Westin; Karen H Lu; Sharon H Giordano; Larissa A Meyer
Journal:  Obstet Gynecol       Date:  2018-07       Impact factor: 7.661

3.  Inadequately Staged Endometrial Cancer: a Clinical Dilemma.

Authors:  Vinotha Thomas; Anitha Thomas; Ajit Sebastian; Rachel Chandy; Abraham Peedicayil
Journal:  Indian J Surg Oncol       Date:  2017-08-07

4.  Prospective assessment of the prevalence of pelvic, paraaortic and high paraaortic lymph node metastasis in endometrial cancer.

Authors:  Sanjeev Kumar; Karl C Podratz; Jamie N Bakkum-Gamez; Sean C Dowdy; Amy L Weaver; Michaela E McGree; William A Cliby; Gary L Keeney; Gillian Thomas; Andrea Mariani
Journal:  Gynecol Oncol       Date:  2013-10-09       Impact factor: 5.482

5.  Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival.

Authors:  Casey M Cosgrove; David E Cohn; Heather Hampel; Wendy L Frankel; Dan Jones; Joseph P McElroy; Adrian A Suarez; Weiqiang Zhao; Wei Chen; Ritu Salani; Larry J Copeland; David M O'Malley; Jeffrey M Fowler; Ahmet Yilmaz; Alexis S Chassen; Rachel Pearlman; Paul J Goodfellow; Floor J Backes
Journal:  Gynecol Oncol       Date:  2017-07-11       Impact factor: 5.482

6.  Feasibility of a reduced field-of-view diffusion-weighted (rFOV) sequence in assessment of myometrial invasion in patients with clinical FIGO stage I endometrial cancer.

Authors:  Priya Bhosale; Jingfei Ma; Revathy Iyer; Preetha Ramalingam; Wei Wei; Pamela Soliman; Michael Frumovitz; Vikas Kundra
Journal:  J Magn Reson Imaging       Date:  2015-07-16       Impact factor: 4.813

7.  Sentinel Lymph Node Mapping in Endometrial Cancer: An Update.

Authors:  Fady Khoury-Collado; Caryn St Clair; Nadeem R Abu-Rustum
Journal:  Oncologist       Date:  2016-03-09

8.  Sentinel lymph node mapping with pathologic ultrastaging: a valuable tool for assessing nodal metastasis in low-grade endometrial cancer with superficial myoinvasion.

Authors:  Christine H Kim; Fady Khoury-Collado; Emma L Barber; Robert A Soslow; Vicky Makker; Mario M Leitao; Yukio Sonoda; Kaled M Alektiar; Richard R Barakat; Nadeem R Abu-Rustum
Journal:  Gynecol Oncol       Date:  2013-10-04       Impact factor: 5.482

Review 9.  Current Issues in the Diagnosis and Treatment of Endometrial Carcinoma.

Authors:  J Stubert; B Gerber
Journal:  Geburtshilfe Frauenheilkd       Date:  2016-02       Impact factor: 2.915

10.  The pattern of myometrial invasion as a predictor of lymph node metastasis or extrauterine disease in low-grade endometrial carcinoma.

Authors:  Elizabeth Euscher; Patricia Fox; Roland Bassett; Hayma Al-Ghawi; Rouba Ali-Fehmi; Denise Barbuto; Bojana Djordjevic; Elizabeth Frauenhoffer; Insun Kim; Sun Rang Hong; Delia Montiel; Elizabeth Moschiano; Andres Roma; Elvio Silva; Anais Malpica
Journal:  Am J Surg Pathol       Date:  2013-11       Impact factor: 6.394

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.